LD-2 disclosure · 1st Quarter - Termination
ENDO PHARMACEUTICALS
Client
- Description
- Pharmaceutical Company
- Location
- District of Columbia · United States of America
Registrant
- Description
- Government Relations Firm
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
2 issuesTaxation/Internal Revenue Code
Taxation/Internal Revenue Code Issues relating to incentives for life sciences research. Treatment of inbound companies in comprehensive tax reform; Treasury regulations relating to Section 385.
LobbyistsDAVID JORY · BRIAN SUTTER · WILLIAM STEVE SOUTHERLAND ii · THOMAS WHARTON · SURYA GABLIN GUNASEKARA
Covered position (BRIAN SUTTER): Staff Dir., W&M Health Subcommittee, Chrman Dave Camp April'13-Dec.'14 Professional Staff, W&M Health Subcommittee, Chrman Dave Camp, Jan'11-April'13 Leg Dir. Rep. Dave Camp, May'08-Jan'11 Leg Asst Rep. Dave Camp, Feb'03-May'08; Staff Ast July'02-
Covered position (WILLIAM STEVE SOUTHERLAND ii): William Steve Southerland, II served as the U.S. Representative for Florida's 2nd congressional district from 2011 to 2015.
Covered position (THOMAS WHARTON): Health Legislative Assistant - Senator Joe Lieberman. May 2011 - June 2012 Senior Legislative Assistant - Congressman Dan Boren. July 2008 - June 2011
Covered position (SURYA GABLIN GUNASEKARA): Chief of Staff and Tax Counsel - Rep. James B. Renacci May 2015 - Aug. 2017.
TargetedSENATE · HOUSE OF REPRESENTATIVES
Health Issues
Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to FDA approvals of new drugs and generic drugs. Issues related to the FDA Issues related to Opioids Issues relating to Medicare Part D rebates. Issues relating to the labeling of generic drugs. Issues relating to CDC guidance for prescribing opioids Issues relating to products containing high doses of acetaminophen. Issues relating to removal of FDA unapproved products from the market Opioid abuse legislation Issues relating to prescription drug pricing. Issues relating to FDA compounding regulations. Issues relating to illegal marketing of phenobarbital Issues relating to FDA approval of adrenaline